Reports that a drug used to treat autoimmune diseases and cancer could also treat CFS have been refuted by a new Griffith University study.
The first non-human primate trials of a dual vaccine developed in Australia for the zika and chikungunya viruses are about to begin in the United States.
Scientists have restored visual responses in blind mice by transplanting artificial replacements for light-detecting cells into their eyes.
Adelaide researchers have developed and patented a novel approach to fight superbugs by targeting the bugs' favourite food, iron.
Zika virus could be used for treatment of glioblastoma, according to Brazilian researchers.
Australian and Dutch researchers have moved a step closer towards making human kidneys from stem cells.
Australian biomedical engineers have combined lab-made peptides with natural proteins and polymers to create a 3D 'hydrogel scaffold'.
A CRISPR-based genetic detective could lead to fast, reliable medical tests.
Researchers have identified a drug that could reverse the damaging impacts of heavy alcohol consumption on the regeneration of brain cells.
US researchers have uncovered the first evidence of a protein that can conduct electricity like a metal — so long as the voltage is high enough.
A recent investigation raises concerns over poor quality, lack of regulation and misrepresentation of animal studies for drug development.
An international collaboration, led by Melbourne researchers, has solved a longstanding malaria mystery.
Dr Michael Gantier, Research Group Head, Nucleic Acids and Innate Immunity at the Hudson Institute in Melbourne, reflects on the latest developments in the field of infection and immunity and his lab's current focus and future plans.
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017 held in Geneva, Switzerland.
Australian researchers have developed a new risk scoring system for children with leukaemia based on missing DNA fragments or ‘microdeletions’.